Sydney Jennings

Editor of Patient Care Online.

Articles

FLOW Trial: Semaglutide Lowers Risk for Major Kidney Disease, CV Events and Death Regardless of SGLT-2i Use

June 25, 2024

ADA 2024. Semaglutide benefits were observed for adults with type 2 diabetes and chronic kidney disease whether or not they used SGLT-2 inhibitors, according to an analysis of FLOW trial data.

Sugar Substitute Raises Risk of Major Adverse Cardiovascular Events: Daily Dose

June 25, 2024

Your daily dose of the clinical news you may have missed.

SURMOUNT-OSA: Tirzepatide Improves Sleep Apnea Symptoms, CV Outcomes in Adults with OSA and Obesity

June 24, 2024

ADA 2024. Adults with OSA and obesity receiving tirzepatide had improvements in sleep apnea severity and systolic blood pressure compared to placebo.

Global Prevalence of T1D Rising in Older Adults: Daily Dose

June 24, 2024

Your daily dose of the clinical news you may have missed.

ADA 84th Scientific Sessions: 3 Studies Primary Care Clinicians Should Put on Their Radar

June 20, 2024

Details on tirzepatide for obesity-related obstructive sleep apnea, semaglutide for prevention of major kidney outcomes in patients with T2D and CKD, more.

Investigational Influenza-COVID-19 Combination Vaccine Elicits Immune Response in Older Adults: Daily Dose

June 20, 2024

Your daily dose of the clinical news you may have missed.

New Report Shows that Despite Gains, Black Americans Still Face Higher Cardiovascular Mortality

June 19, 2024

Between 2000 and 2022, there were nearly 800 000 excess CV deaths among Black Americans and 24 million additional years of life lost, researchers report.

Investigational RNAi Agent Cuts Triglyceride Levels in Patients with Mixed Hyperlipidemia: Daily Dose

June 18, 2024

Your daily dose of the clinical news you may have missed.

ADA 84th Scientific Sessions Preview: STEP-HFp-EF Trial Data, Tirzepatide for Obesity-Related OSA, Optimizing Diabetes Care in Primary Care

June 17, 2024

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Tirzepatide Superior to Placebo in MASH Resolution, Fibrosis Improvement: Daily Dose

June 17, 2024

Your daily dose of the clinical news you may have missed.